ModifiedColorado Rocky Mountain Health PlansPolicy 2026D0039W

Orencia (abatacept) Injection for Intravenous Infusion

Medical policy governing coverage and prior authorization criteria for Orencia (abatacept) administered by intravenous infusion for UnitedHealthcare Commercial and Individual Exchange plans. Affects providers prescribing or administering Orencia for listed indications.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyOrencia (abatacept) Injection for Intravenous Infusion

Policy CodePolicy 2026D0039W

Change TypeContent and operational updates (revised language, added agent, template migration)

Effective DateJun 1, 2026

Next Review Date

Key ActionObtain prior authorization with indication-specific documentation and follow authorization limits (generally up to 12 months; select indications limited to 4 doses).

SourceLink

POLICY UPDATE CHANGES

Replaced references to 'targeted immunomodulator' with 'systemic targeted immunomodulator' and updated coverage criteria and lists of systemic targeted immunomodulators for multiple indications.

Replaced 'Xeljanz (tofacitinib)' with 'Xeljanz/ Xeljanz XR (tofacitinib)' throughout relevant criteria and lists.

Added Bimzelx (bimekizumab-bkzx) to the list of systemic targeted immunomodulators the patient must not be receiving in combination with Orencia for psoriatic arthritis.

Template update transferred content to a shared policy template and added an Application section specifying plan applicability to UnitedHealthcare Commercial and Individual Exchange benefit plans.

12 monthsusual initial/continuation authorization length

4 dosesauthorization limit (aGVHD / ICI toxicities)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Orencia (abatacept) IV Infusion

Polyarticular juvenile idiopathic arthritis (PJIA)

Covered when ALL of the following are met

PJIA Initial Therapy: Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis (PJIA); and Orencia is initiated and titrated according to U.S. Food and Drug Administration (FDA) labeled dosing for PJIA; and Patient is not receiving Orencia in combination with a systemic targeted immunomodulator (e.g., adalimumab, certolizumab, etanercept, baricitinib, upadacitinib, golimumab, tofacitinib) for treatment of the same indication; and Initial authorization is for no more than 12 months

PJIA Continuation: Patient has previously received Orencia injection for intravenous infusion; and Documentation of positive clinical response; and Orencia is dosed according to FDA labeled dosing for PJIA; and Patient is not receiving Orencia in combination with a systemic targeted immunomodulator for treatment of the same indication; and Authorization is for no more than 12 months

Rheumatoid arthritis (RA)

Covered when ALL of the following are met

RA Initial Therapy - entry criteria: Diagnosis of moderately to severely active rheumatoid arthritis (RA); and One of the following: history of failure or intolerance to a 3-month trial of a non-biologic DMARD at maximally indicated doses unless contraindicated; or prior treatment with a systemic targeted immunomodulator FDA-approved for RA; or patient is currently on Orencia;

RA Initial Therapy - additional: Orencia is initiated and titrated according to FDA labeled dosing for RA; and Patient is not receiving Orencia in combination with a systemic targeted immunomodulator for treatment of the same indication; and Prescribed by or in consultation with a rheumatologist; and Initial authorization is for no more than 12 months

RA Continuation: Patient has previously received Orencia injection for intravenous infusion; and Documentation of positive clinical response; and Orencia is dosed according to FDA labeled dosing for RA; and Patient is not receiving Orencia in combination with a systemic targeted immunomodulator for treatment of the same indication; and Authorization is for no more than 12 months

Psoriatic arthritis (PsA)

Covered when ALL of the following are met

PsA Initial Therapy - entry criteria: Diagnosis of active psoriatic arthritis (PsA); and One of the following: history of failure to a 3-month trial of methotrexate at the maximally indicated dose unless contraindicated; or prior treatment with a systemic targeted immunomodulator FDA-approved for PsA; or patient is currently on Orencia;

PsA Initial Therapy - additional: Orencia is initiated and titrated according to FDA labeled dosing for PsA; and Patient is not receiving Orencia in combination with a systemic targeted immunomodulator for treatment of the same indication (examples listed in policy); and Prescribed by or in consultation with a rheumatologist or dermatologist; and Initial authorization is for no more than 12 months

PsA Continuation: Patient has previously received Orencia injection for intravenous infusion; and Documentation of a positive clinical response; and Orencia is dosed according to FDA labeled dosing for PsA; and Patient is not receiving Orencia in combination with a systemic targeted immunomodulator for treatment of the same indication; and Authorization is for no more than 12 months

Chronic graft-versus-host disease (cGVHD)

Proven and/or medically necessary when ALL of the following are met

cGVHD Initial Therapy: Diagnosis of steroid-refractory chronic graft-versus-host disease (cGVHD); and One of the following: patient is receiving Orencia in combination with systemic corticosteroids; or patient is intolerant to systemic corticosteroid therapy; and Initial authorization is for no more than 12 months

cGVHD Continuation: Documentation of positive clinical response; and Patient continues to experience chronic GVHD; and One of the following: patient is receiving Orencia in combination with systemic corticosteroids; or patient is intolerant to systemic corticosteroid therapy; or patient has been successfully tapered off corticosteroid therapy; and Authorization is for no more than 12 months

Prophylaxis of acute graft-versus-host disease (aGVHD)

Proven and/or medically necessary when ALL of the following are met

aGVHD Prophylaxis: Patient is at least 2 years old; and Patient is undergoing hematopoietic stem cell transplantation (HSCT) from a matched donor or from a 1 allele-mismatched unrelated donor; and Patient is receiving Orencia in combination with a calcineurin inhibitor and methotrexate; and Authorization is for no more than 4 doses

Document donor HLA match status and concomitant CNI + MTX when requesting authorization.

Immune checkpoint inhibitor (ICI)-related toxicities

Proven and/or medically necessary when ALL of the following are met

ICI Toxicities: Patient has recently received checkpoint inhibitor therapy (e.g., pembrolizumab, nivolumab); and Diagnosis of severe (G3) or life threatening (G4) immunotherapy-related myocarditis, pericarditis, arrhythmias, impaired ventricular function, or conduction abnormalities; and No improvement within 24 hours of starting pulse-dose methylprednisolone; and History of failure, contraindication, or intolerance to infliximab; and Authorization is for no more than 4 doses

Documentation should include prior checkpoint inhibitor exposure, failure to improve after high‑dose steroids, and prior infliximab trial or contraindication.

Combination therapy — limited coverage

Covered when ALL of the following are met

Combination therapy coverage: Patient is receiving Orencia in combination with a calcineurin inhibitor; and Patient is receiving Orencia in combination with methotrexate; and Authorization is for no more than 4 doses

Used in the context of HSCT aGVHD prophylaxis where combination with CNI + MTX is required.

Immune checkpoint inhibitor-related cardiac toxicity — rescue therapy

Covered when ALL of the following are met

Checkpoint inhibitor-related toxicity criteria: Patient has recently received checkpoint inhibitor therapy; and Diagnosis of severe (G3) or life threatening (G4) immunotherapy-related myocarditis, pericarditis, arrhythmias, or impaired ventricular function, or conduction abnormalities; and No improvement of toxicity within 24 hours of starting pulse-dose methylprednisolone; and History of failure, contraindication, or intolerance to infliximab; and Authorization is for no more than 4 doses

NCCN notes abatacept can be used for myocarditis if no improvement within 24–48 hours of high‑dose methylprednisolone; policy requires 24 hours and prior infliximab failure/contraindication/intolerance.

Supported clinical indications

Evidence-supported indications summarized from randomized trials and long-term studies

Indications with supporting RCT or long-term evidence: Psoriatic arthritis, rheumatoid arthritis (SC and IV formulations), early RA in combination with methotrexate, and polyarticular juvenile idiopathic arthritis have randomized controlled trial evidence of efficacy and safety for abatacept (see cited Phase 3 PsA trial, Phase 3b RA SC vs IV trial, AVERT early RA trial, and PJIA Phase 3 studies); Trial endpoints include ACR20, DAS28(CRP) remission, and JIA-ACR responses;

Long-term extension data support sustained efficacy and safety in PJIA (up to 7 years) and RA formulations showed comparable SC and IV efficacy.

Evidence-supported indications and guideline context

Evidence-supported clinical contexts where abatacept has demonstrated efficacy or is recommended by guidelines

Polyarticular JIA (pediatric): SC abatacept with weight-tiered dosing demonstrated target trough concentrations (Cminss >= 10 µg/ml) and robust JIA-ACR responses at month 4 with maintenance to month 24; long-term extension data up to 7 years support sustained efficacy and safety.age 2-17 in trials; weight-tiered dosing: 50 mg (10-<25 kg), 87.5 mg (25-<50 kg), 125 mg (>=50 kg)

Immunogenicity was low and did not have clinical effects.

GVHD prophylaxis (HSCT): Abatacept given IV at 10 mg/kg (max 1000 mg) on Day -1, 5, 14, and 28 in combination with a calcineurin inhibitor and methotrexate reduced grade II-IV GVHD and improved Day 180 overall survival in 8/8 cohorts and showed favorable exploratory results in 7/8 cohorts.studied in patients >=6 years in trials; donor match 8/8 or 7/8 URD

CIBMTR analysis showed Day 180 OS 98% vs 75% comparator in mixed cohorts.

Covered when meeting guideline-based clinical criteria and FDA indications

Guideline-based conditional recommendations and FDA indications informing coverage considerations

JIA biologic initiation: For children/adolescents with polyarticular JIA initiating a biologic (etanercept, adalimumab, golimumab, abatacept, or tocilizumab), combination therapy with a DMARD is conditionally recommended over biologic monotherapy; subsequent therapy is guided by cJADAS-10 > 2.5 for moderate/high disease activity.cJADAS-10 > 2.5

Guideline-based conditional recommendation.

NTM lung disease recommendations: In patients with nontuberculous mycobacterial (NTM) lung disease, use the lowest possible glucocorticoid dose and prefer adding csDMARDs over bDMARDs/tsDMARDs; abatacept is conditionally recommended over other bDMARDs/tsDMARDs for patients with moderate-to-high disease activity despite csDMARDs.prior serious infection within 12 months influences choice

Preference based on infection risk considerations.

The policy prohibits concurrent use of Orencia (abatacept) with another systemic targeted immunomodulator for treatment of the same indication. Examples listed in the policy include agents such as adalimumab, certolizumab (Cimzia), etanercept (Enbrel), baricitinib (Olumiant), upadacitinib (Rinvoq), golimumab (Simponi), and tofacitinib (Xeljanz/Xeljanz XR) for several indications; the psoriatic arthritis examples additionally include bimekizumab (Bimzelx), secukinumab (Cosentyx), risankizumab (Skyrizi), ixekizumab (Taltz), guselkumab (Tremfya), ustekinumab, and apremilast (Otezla). Coverage criteria require that the patient is not receiving Orencia in combination with a systemic targeted immunomodulator for the same indication as a condition of initial or continued authorization.

The policy identifies several uses as unproven or not medically necessary: specifically multiple sclerosis (RRMS), systemic lupus erythematosus (SLE), and uveitis associated with Behçet's disease. The evidence cited includes randomized trials in RRMS that failed to show benefit (ACCLAIM and a separate Phase II study) and a Phase II SLE trial that did not meet its primary endpoint; for Behçet's-associated uveitis the policy states there is insufficient published clinical evidence to support use.

Benefit and coverage decisions must be verified against the member’s specific certificate of coverage. The policy notes that some Certificates of Coverage may permit coverage of experimental or off‑label uses under defined conditions and that state mandates can supersede policy language; therefore, providers should confirm benefit-specific exclusions and any applicable state requirements before assuming denial or approval.

Clinical trial evidence in the document does not support abatacept for certain indications: randomized RRMS trials failed to demonstrate reductions in new gadolinium‑enhancing MRI lesions or clinical benefit and one trial was stopped early for safety concerns in a lower‑dose arm; a Phase II SLE trial failed to meet its primary endpoint for reduction in new flares; and published evidence for Behçet's uveitis is described as insufficient. The policy therefore characterizes these indications as not supported by the cited evidence.

The FDA labeling and policy commentary warn against concurrent administration of Orencia with tumor necrosis factor (TNF) antagonists or certain other biologic RA therapies because trials showed higher infection rates and no demonstrated superiority for the combination. As a result, the policy treats such concurrent combinations as unsupported and requires documentation that Orencia is not being given concomitantly with TNF antagonists or other biologic RA therapies when relevant.

The policy specifically calls out use of abatacept as unproven for multiple sclerosis, systemic lupus erythematosus, and uveitis associated with Behçet's disease, summarizing that randomized trials and peer‑reviewed literature do not provide sufficient evidence of efficacy or safety for these indications.

Although the policy lists specific unproven indications, the excerpt does not present a separate, explicit enumeration titled 'not medically necessary' beyond those entries; it emphasizes that plan‑level benefit documents and state mandates may also define exclusions or coverage for off‑label uses.

The policy references trial-level evidence showing that abatacept did not demonstrate clinical benefit in the cited RRMS studies (no significant reduction in new Gd+ MRI lesions and other clinical measures) and that the SLE Phase II trial failed to meet its primary endpoint for reducing new flares; for Behçet's uveitis the policy states there is insufficient published evidence. These trial outcomes underpin the conclusion that abatacept is not supported for these indications in the cited sections.

Clinical trials that combined Orencia with TNF antagonists reported increased overall and serious infections and did not show superiority for combination therapy. The FDA labeling therefore states that Orencia should not be administered concomitantly with TNF antagonists, a principle reflected in the policy's guidance against concurrent use.

Coding and Diagnosis References

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for abatacept (Orencia) for indication-specific uses including polyarticular juvenile idiopathic arthritis (PJIA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), chronic GVHD, prophylaxis of acute GVHD (aGVHD), and immune checkpoint inhibitor (ICI)-related toxicities. Requests must include diagnosis, dosing consistent with FDA labeling, prescriber specialty when specified (eg, rheumatologist, dermatologist), and documentation of prior treatment trials or intolerance where indicated. Initial and continuation authorizations are typically limited to no more than 12 months unless otherwise noted.

Indication-specific PA required: PJIA, RA, PsA, chronic GVHD, aGVHD prophylaxis, ICI-related toxicities
Prescriber specialties required where specified (eg, rheumatologist for RA/PJIA; rheumatologist or dermatologist for PsA)
Documentation: diagnosis, ICD-10 code, FDA-consistent dosing, prior therapy history, and objective clinical response for continuation

Prior Authorization

Prior Authorization and Dose Limit

Some indications have prior authorization with dose or quantity limits. For aGVHD prophylaxis and ICI-related toxicity treatment, prior authorization limits authorization to up to 4 doses. Initial authorizations for most chronic indications are limited to no more than 12 months.

Background and Clinical Context

Background: Orencia (abatacept) is a selective co‑stimulation modulator — a fully human, soluble fusion protein that inhibits T‑lymphocyte activation by binding CD80 and CD86 to block CD28‑mediated co‑stimulation. It is indicated for adult rheumatoid arthritis, pediatric polyarticular juvenile idiopathic arthritis (≥2 years), and adult psoriatic arthritis, and may be used as monotherapy or with certain DMARDs but not with TNF antagonists per labeling.

Definitions and Key Terms

Initial therapy / Continuation of therapy — operational definitions and brief requirements

Initial therapy — entry requirementsDiagnosis per indication and Orencia initiated/titrated per FDA-labeled dosing; patient not receiving Orencia with a systemic targeted immunomodulator for same indication

Continuation — documentationPrior receipt of Orencia IV, documentation of positive clinical response, dosing per FDA labeling, and no concurrent systemic targeted immunomodulator for same indication

Authorization durationInitial and continuation authorizations generally limited to no more than 12 months for most indications

Severe (G3) or life threatening (G4) immunotherapy-related myocarditis/pericarditis/arrhythmia — definition used in ICI-related toxicity criteria

Definition (severity classes)Clinical diagnoses of myocarditis, pericarditis, arrhythmias, impaired ventricular function, or conduction abnormalities related to checkpoint inhibitor therapy classified as severe (Grade 3) or life‑threatening (Grade 4)

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyOrencia (abatacept) Injection for Intravenous Infusion

Policy CodePolicy 2026D0039W

Change TypeContent and operational updates (revised language, added agent, template migration)

Effective DateJun 1, 2026

Next Review Date

Key ActionObtain prior authorization with indication-specific documentation and follow authorization limits (generally up to 12 months; select indications limited to 4 doses).

SourceLink

On This Page

Documentation Required

Benefit and Prior Authorization Verification

Verify member-specific benefits and any state-mandated coverage that may supersede policy language before making coverage determinations. Some Certificates of Coverage may allow experimental/investigational or off-label uses under defined conditions; confirm eligibility via the member's benefit plan.

Consult the member-specific Certificate of Coverage and benefit documents
State mandates for off-label coverage may supersede this policy

Prior Authorization

GVHD Prophylaxis — Prior Authorization Note

For prophylaxis of acute GVHD, prior authorization requests must document the HSCT donor HLA match status (8/8 or 7/8), and that abatacept will be administered in combination with both a calcineurin inhibitor (CNI) and methotrexate (MTX). Include clinical rationale and transplant regimen details.

Document donor HLA match (8/8 vs 7/8) and HSCT details
Confirm concomitant use of CNI + methotrexate
Authorization note: up to 4 doses (per study dosing Days -1, 5, 14, 28)

Denial Risk

Concurrent Targeted Immunomodulator or Missing Prior Therapy

Requests may be non-covered or denied if required prior therapy trials are missing or if the patient is concurrently receiving another systemic targeted immunomodulator for the same indication (eg, TNF inhibitors, JAK inhibitors, IL-17/12-23/23 agents). Concurrent use with TNF antagonists or other biologic RA therapies is not supported due to increased infection risk.

Do not authorize if patient is concurrently on systemic targeted immunomodulator for same indication (examples listed in criteria)
Concurrent Orencia + TNF antagonist or other biologic RA therapy is contraindicated per labeling due to increased infections

Denial Risk

Requests for Orencia for Immune Checkpoint–Related Toxicities

For immune checkpoint inhibitor-related toxicities, prior authorization requires documentation of recent checkpoint inhibitor exposure, severity grading (severe G3 or life-threatening G4 myocarditis/pericarditis/arrhythmia/ventricular dysfunction or conduction abnormalities), lack of improvement after 24 hours of pulse-dose methylprednisolone, and history of failure, contraindication, or intolerance to infliximab when applicable. Requests lacking these elements may be denied.

Document recent ICI therapy and specific cardiac toxicity grade (G3/G4)
Document ≥24 hours without improvement on pulse-dose methylprednisolone
Document failure/contraindication/intolerance to infliximab (when required)
Authorization limited to up to 4 doses

Documentation Required

Documentation Should Support Concomitant Use

When requesting concomitant use (eg, with CNI + MTX for aGVHD prophylaxis or with systemic corticosteroids for chronic GVHD), provide supporting documentation: dosing schedules, transplant regimen, corticosteroid use/tapering plan, and rationale for combined therapy.

Include transplant regimen and timing (days relative to HSCT) for aGVHD prophylaxis requests
For chronic GVHD, document concurrent systemic corticosteroid use or intolerance to corticosteroids and taper plans

Documentation Required

Clinical Evidence and Pediatric Dosing

For pediatric indications (PJIA and aGVHD prophylaxis in appropriate ages), include clinical evidence and pediatric dosing details in the request: study cohorts, weight-tiered dosing (for SC abatacept in PJIA), IV dosing schema for aGVHD studies (10 mg/kg with 1,000 mg maximum on Days -1, 5, 14, 28), and clinical response measures. Provide long-term safety/efficacy data when available to support continuation requests.

PJIA: include study cohort age, weight-tiered SC dosing (50 mg, 87.5 mg, 125 mg tiers) and JIA-ACR/JADAS response data where available
aGVHD prophylaxis: include IV dosing (10 mg/kg, max 1,000 mg) and dosing days relative to HSCT
Include pediatric safety and long-term extension study data when requesting continuation

Documentation Required

Concomitant Therapy and Self-Injection Documentation

Document non-concomitance with TNF antagonists and other biologic RA therapies. When self-injection is planned, document that the patient or caregiver received training and is capable of proper administration per the product Instructions for Use.

Statement that Orencia will not be used concurrently with TNF antagonists or other biologic RA therapies
For SC self-injection, document patient/caregiver training and suitability for self-administration

Step Therapy

Step Therapy Requirements for RA and PsA

Step therapy requirements for RA and PsA: RA initial therapy generally requires failure or intolerance to a 3-month trial of a non-biologic DMARD (eg, methotrexate) at maximally indicated doses unless contraindicated, OR prior treatment with an FDA‑approved systemic targeted immunomodulator for RA, or current use of Orencia. For PsA, initial therapy generally requires failure of a 3-month trial of methotrexate at maximally indicated dose unless contraindicated, OR prior treatment with an FDA‑approved systemic targeted immunomodulator for PsA, or current use of Orencia. Prescriber consultation requirements (eg, rheumatologist/dermatologist) apply where specified.

RA: trial of 3 months of one csDMARD unless contraindicated, or prior targeted therapy, or current Orencia use
PsA: trial of 3 months methotrexate unless contraindicated, or prior targeted therapy, or current Orencia use
Prescribed by or in consultation with appropriate specialist as specified

Step Therapy

Step Therapy Preference Guidance and Guideline‑Informed Sequencing

Guideline-informed sequencing and class preference: clinical guidance generally prefers TNF inhibitors, IL-17, or IL‑12/23 agents over abatacept for PsA in many settings; abatacept may be considered in patients with contraindications to preferred classes or with recurrent/serious infections. For JIA, guidelines support adding or switching to abatacept or other non‑TNFi biologics based on prior response and disease activity. Document rationale when deviating from guideline sequencing.

PsA: prefer TNFi, IL-17i, or IL-12/23i over abatacept unless contraindicated or patient‑specific reasons documented
JIA: consider combination with DMARDs and sequence to abatacept or other non‑TNFi biologics per ACR guidance when appropriate
Document clinical rationale when choosing abatacept outside preferred sequencing

csDMARD / bDMARD / tsDMARD — definition of conventional synthetic, biologic, and targeted synthetic DMARD classes

csDMARD definitionConventional synthetic disease‑modifying antirheumatic drugs (csDMARDs) — e.g., methotrexate; preferred initial csDMARD in RA/JIA per guidelines

bDMARD definitionBiologic DMARDs (bDMARDs) — biologic agents including TNF inhibitors, abatacept, tocilizumab, etc., used after csDMARDs or for specific indications

tsDMARD definitionTargeted synthetic DMARDs (tsDMARDs) — small‑molecule agents (e.g., JAK inhibitors) referenced in guideline sequencing and combination decisions